Kusajili – Clinical trials directory

Result of your search per sponsor: Sören Lehmann, MD, PhD

Woman and Man Max 99 years
Sören Lehmann, MD, PhD Update Il y a 5 ans

Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer The purpose of this study is to determine the highest feasible dose (HFD) of intravenous (IV) APR-246 when given to patients with refractory hematologic malignancies or prostate carcinoma.

Country Sweden
organs None
Specialty None

Closed trial

More information